-
Je něco špatně v tomto záznamu ?
A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial
C. Grimm, S. Polterauer, S. Helmy-Bader, M. Zikan, D. Cibula, F. Heitz, P. Harter, A. Giese, A. Reinthaller, C. Tempfer,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- jednoduchá slepá metoda MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfadenektomie škodlivé účinky metody MeSH
- lymfokela etiologie prevence a kontrola MeSH
- nádory ženských pohlavních orgánů chirurgie MeSH
- pooperační komplikace etiologie prevence a kontrola MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
OBJECTIVE: To evaluate the efficacy of a collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies. METHODS: In a multicenter, randomized, clinical trial, 164 women with pelvic lymphadenectomy were allocated either to bilateral pelvic application of two collagen-fibrin patches or no intervention. Main outcome was efficacy, defined as reduction of symptomatic lymphocele rate diagnosed within four weeks after surgery. Secondary outcomes were asymptomatic lymphoceles and subsequent interventions. Sample size was based on the assumption that application of a collagen-fibrin patch reduces the prevalence of symptomatic lymphoceles by at least 66%. The study was single-blinded, i.e., patients and primary outcome assessors, but not surgeons, were blinded to the treatment allocation. RESULTS: A total of 75 women were randomized to the intervention and 89 to the control group. All women received the allocated intervention. In total, 42 (27.4%) lymphoceles and 8 (5.2%) symptomatic lymphoceles were observed. Symptomatic lymphoceles were observed in 5/68 (7.4%) women in the intervention group and 3/85 (3.5%) women in the control group (p = 0.47). Asymptomatic lymphoceles were observed in 16 (23.5%) women in the intervention group compared to 18 (21.2%) in the control group (p = 0.85). In a multivariate logistic regression model, no independent risk factor for the development of a symptomatic lymphocele was ascertained. DISCUSSION: Intraoperative application of collagen-fibrin patches to the pelvic side walls does not reduce the incidence of symptomatic lymphoceles in women with gynecologic malignancies undergoing pelvic lymphadenectomy.
Department of Gastroenterology St Josef Hospital Bochum Germany
Department of Gynecology and Gynecologic Oncology Kliniken Essen Mitte Essen Germany
Department of Obstetrics and Gynecology Ruhr University Bochum Bochum Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033349
- 003
- CZ-PrNML
- 005
- 20181024151319.0
- 007
- ta
- 008
- 181008s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ygyno.2018.01.012 $2 doi
- 035 __
- $a (PubMed)29395308
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Grimm, Christoph $u Department of General Gynecology and Gynecologic Oncology, Comprehensive Cancer Center, Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria.
- 245 12
- $a A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial / $c C. Grimm, S. Polterauer, S. Helmy-Bader, M. Zikan, D. Cibula, F. Heitz, P. Harter, A. Giese, A. Reinthaller, C. Tempfer,
- 520 9_
- $a OBJECTIVE: To evaluate the efficacy of a collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies. METHODS: In a multicenter, randomized, clinical trial, 164 women with pelvic lymphadenectomy were allocated either to bilateral pelvic application of two collagen-fibrin patches or no intervention. Main outcome was efficacy, defined as reduction of symptomatic lymphocele rate diagnosed within four weeks after surgery. Secondary outcomes were asymptomatic lymphoceles and subsequent interventions. Sample size was based on the assumption that application of a collagen-fibrin patch reduces the prevalence of symptomatic lymphoceles by at least 66%. The study was single-blinded, i.e., patients and primary outcome assessors, but not surgeons, were blinded to the treatment allocation. RESULTS: A total of 75 women were randomized to the intervention and 89 to the control group. All women received the allocated intervention. In total, 42 (27.4%) lymphoceles and 8 (5.2%) symptomatic lymphoceles were observed. Symptomatic lymphoceles were observed in 5/68 (7.4%) women in the intervention group and 3/85 (3.5%) women in the control group (p = 0.47). Asymptomatic lymphoceles were observed in 16 (23.5%) women in the intervention group compared to 18 (21.2%) in the control group (p = 0.85). In a multivariate logistic regression model, no independent risk factor for the development of a symptomatic lymphocele was ascertained. DISCUSSION: Intraoperative application of collagen-fibrin patches to the pelvic side walls does not reduce the incidence of symptomatic lymphoceles in women with gynecologic malignancies undergoing pelvic lymphadenectomy.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a nádory ženských pohlavních orgánů $x chirurgie $7 D005833
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfadenektomie $x škodlivé účinky $x metody $7 D008197
- 650 _2
- $a lymfokela $x etiologie $x prevence a kontrola $7 D008210
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pooperační komplikace $x etiologie $x prevence a kontrola $7 D011183
- 650 _2
- $a jednoduchá slepá metoda $7 D016037
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Polterauer, Stephan $u Department of General Gynecology and Gynecologic Oncology, Comprehensive Cancer Center, Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Helmy-Bader, Samir $u Department of General Gynecology and Gynecologic Oncology, Comprehensive Cancer Center, Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Zikan, Michal $u Department of Obstetrics and Gynecology, Gynecologic Oncology Center, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Cibula, David $u Department of Obstetrics and Gynecology, Gynecologic Oncology Center, Charles University Prague, Prague, Czech Republic.
- 700 1_
- $a Heitz, Florian $u Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany.
- 700 1_
- $a Harter, Philipp $u Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany.
- 700 1_
- $a Giese, Arnd $u Department of Obstetrics and Gynecology, Ruhr University Bochum, Bochum, Germany; Department of Gastroenterology, St. Josef Hospital, Bochum, Germany.
- 700 1_
- $a Reinthaller, Alexander $u Department of General Gynecology and Gynecologic Oncology, Comprehensive Cancer Center, Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Tempfer, Clemens $u Department of Obstetrics and Gynecology, Ruhr University Bochum, Bochum, Germany. Electronic address: clemens.tempfer@rub.de.
- 773 0_
- $w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 149, č. 1 (2018), s. 140-145
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29395308 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181024151827 $b ABA008
- 999 __
- $a ok $b bmc $g 1339434 $s 1030343
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 149 $c 1 $d 140-145 $e 20180212 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
- LZP __
- $a Pubmed-20181008
